DOCSLIB.ORG

Blueprint Genetics Charcot-Marie-Tooth Neuropathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Charcot-Marie-Tooth Neuropathy Panel Test code: NE1301 Is a 105 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of Charcot-Marie-Tooth neuropathy. About Charcot-Marie-Tooth Neuropathy Charcot-Marie-Tooth (CMT) neuropathy, also known as hereditary motor/sensory neuropathy (HMSN) is the most common genetic cause of neuropathy. Prevalence is estimated to be 1:3,300. CMT is characterized by broad genetic heterogeneity and can be inherited in an autosomal dominant, autosomal recessive or X-linked manner. CMT neuropathy results from involvement of peripheral nerves that can affect the motor system and/or the sensory system. Individuals with CMT experience symmetric, slowly progressive distal motor neuropathy of the arms and legs usually beginning in the first to third decade of life, and resulting in weakness and atrophy of the muscles in the feet and/or hands. Pes cavus foot deformity is common. CMT neuropathies can be divided to demyelinating and axonal forms. Availability 4 weeks Gene Set Description Genes in the Charcot-Marie-Tooth Neuropathy Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD AARS Epileptic encephalopathy, early infantile, Charcot-Marie-Tooth disease AD/AR 9 16 AGTPBP1 Neuropathy AR 3 1 AIFM1 Deafness, Combined oxidative phosphorylation deficiency 6, Cowchock XL 27 31 syndrome AMACR Alpha-methylacyl-CoA racemase deficiency, Bile acid synthesis defect AR 3 8 ARHGEF10 Slowed nerve conduction velocity AD 4 12 ATAD3A* Harel-Yoon syndrome AD/AR 4 17 ATL1 Spastic paraplegia, Neuropathy, hereditary sensory AD 29 84 ATL3 Neuropathy, hereditary sensory AD 1 4 ATP1A1 Charcot-Marie-Tooth disease AD 8 10 ATP7A Menkes disease, Occipital horn syndrome, Spinal muscular atrophy, distal, XL 116 354 X-linked 3 BAG3 Dilated cardiomyopathy (DCM), Myopathy, myofibrillar AD 39 62 BICD2 Childhood-onset proximal spinal muscular atrophy with contractures AD 12 28 https://blueprintgenetics.com/ BSCL2 Lipodystrophy, congenital generalized, Encephalopathy, progressive, AD/AR 34 50 Neuropathy, distal hereditary motor, type VA, Charcot-Marie-Tooth disease type 2, Silver syndrome, Silver spastic paraplegia syndrome, Spastic paraplegia 17 C12ORF65 Spastic paraplegia, Combined oxidative phosphorylation deficiency AR 10 11 CCT5 Neuropathy, hereditary sensory, with spastic paraplegia AR 1 1 CHCHD10 Myopathy, isolated mitochondrial, Frontotemporal dementia and/or AD 4 26 amyotrophic lateral sclerosis 2, Spinal muscular atrophy, Jokela type COA7 Spinocerebellar ataxia, Charcot-Marie-Tooth disease AR 2 7 COX10* Leigh syndrome, Mitochondrial complex IV deficiency AR 52 13 COX6A1 Charcot-Marie-Tooth disease AR 2 1 CTDP1 Congenital cataracts, facial dysmorphism, and neuropathy AR 1 1 DCAF8 Giant axonal neuropathy 2, autosomal dominant AD 1 1 DCTN1 Perry syndrome, Neuropathy, distal hereditary motor AD 10 52 DHTKD1 2-aminoadipic and 2-oxoadipic aciduria, Charcot-Marie-Tooth disease AD/AR 11 18 DNM2 Myopathy, Lethal akinesia and musculoskeletal abnormalities, with brain AD/AR 28 47 and retinal hemorrhages, Charcot-Marie-Tooth disease DNMT1 Neuropathy, hereditary sensory, Cerebellar ataxia, deafness, and AD 9 20 narcolepsy DST Neuropathy, hereditary sensory and autonomic AR 13 7 DYNC1H1 Spinal muscular atrophy, Charcot-Marie-Tooth disease, Mental retardation AD 60 71 EGR2 Neuropathy, Dejerine-Sottas disease, Charcot-Marie-Tooth disease AD/AR 13 21 FAM134B Neuropathy, hereditary sensory and autonomic AR 8 5 FBLN5 Cutis laxa, Macular degeneration, age-related AD/AR 13 22 FGD4 Charcot-Marie-Tooth disease AR 21 27 FIG4 Amyotrophic lateral sclerosis, Polymicrogyria, bilateral occipital, Yunis- AD/AR 34 69 Varon syndrome, Charcot-Marie-Tooth disease FXN* Friedreich ataxia AR 13 63 GAN Giant axonal neuropathy AR 18 76 GARS Neuropathy, distal hereditary motor, Charcot-Marie-Tooth disease AD 19 38 GDAP1 Charcot-Marie-Tooth disease AD/AR 39 100 GJB1 Charcot-Marie-Tooth neuropathy XL 98 495 GNB4 Charcot-Marie-Tooth disease AD 2 5 GNE Proximal myopathy and ophthalmoplegia, Nonaka myopathy, Sialuria AD/AR 78 214 https://blueprintgenetics.com/ HADHB Trifunctional protein deficiency AR 20 65 HARS* Charcot-Marie-Tooth disease, axonal, type 2W, Usher syndrome, type 3B AR 6 12 HINT1 Axonal neuropathy with neuromyotonia AR 11 15 HK1 Hemolytic anemia, nonspherocytic, due to hexokinase deficiency, Retinitis AD/AR 9 7 pigmentosa 79, Neuropathy, motor and sensory, Russe type (Charcot- Marie-Tooth disease type 4G) HSPB1 Neuropathy, distal hereditary motor, Charcot-Marie-Tooth disease AD 27 44 HSPB8 Charcot-Marie-Tooth disease, Distal hereditary motor neuronopathy AD 6 9 IGHMBP2 Spinal muscular atrophy, distal, Charcot-Marie-Tooth disease AR 52 128 IKBKAP Dysautonomia, familial, Hereditary sensory and autonomic neuropathy AR 47 6 INF2 Glomerulosclerosis, Charcot-Marie-Tooth disease AD 20 67 KARS Charcot-Marie-Tooth disease AR 9 23 KIF1A Spastic paraplegia, Neuropathy, hereditary sensory, Mental retardation AD/AR 63 42 KIF1B Pheochromocytoma, Neuroblastoma, Charcot-Marie-Tooth disease, type AD 7 12 2A1 KIF5A Spastic paraplegia AD 18 62 LDB3 Dilated cardiomyopathy (DCM), Myopathy, myofibrillar AD 9 14 LITAF Charcot-Marie-Tooth disease AD 10 18 LMNA Heart-hand syndrome, Slovenian, Limb-girdle muscular dystrophy, AD/AR 250 564 Muscular dystrophy, congenital, LMNA-related, Lipodystrophy (Dunnigan), Emery-Dreiffus muscular dystrophy, Malouf syndrome, Dilated cardiomyopathy (DCM), Mandibuloacral dysplasia type A, Progeria Hutchinson-Gilford type LRSAM1 Charcot-Marie-Tooth disease AD/AR 15 14 MARS Interstitial lung and liver disease, Charcot-Marie-Tooth disease, Charcot- AD/AR 9 13 Marie-Tooth disease, axonal, type 2U MCM3AP Charcot-Marie-Tooth neuropathy AR 8 19 MED25 Basel-Vanagait-Smirin-Yosef syndrome, Charcot-Marie-Tooth disease AR 4 5 MFN2 Hereditary motor and sensory neuropathy, Charcot-Marie-Tooth disease AD/AR 70 223 MME Spinocerebellar ataxia 43, Charcot-Marie-Tooth disease, axonal, type 2T AD/AR 14 21 MORC2 Charcot-Marie-Tooth disease type, axonal, type 2Z AD 6 17 MPZ Neuropathy, Roussy-Levy syndrome, Dejerine-Sottas disease, Charcot- AD 108 241 Marie-Tooth disease MTMR2 Charcot-Marie-Tooth disease AR 13 23 MYOT Myopathy, myofibrillar, Muscular dystrophy, limb-girdle, 1A, Myopathy, AD 6 16 spheroid body https://blueprintgenetics.com/ NDRG1 Charcot-Marie-Tooth disease AR 6 8 NEFH* Charcot-Marie-Tooth disease, axonal, type 2CC AD/AR 4 21 NEFL Charcot-Marie-Tooth disease AD 24 40 NGF Neuropathy, hereditary sensory and autonomic AR 2 6 NTRK1 Insensitivity to pain, congenital, with anhidrosis, Medullary thyroid AR 38 123 carcinoma, familial PDK3 Charcot-Marie-Tooth disease XL 1 3 PLEKHG5 Spinal muscular atrophy, Charcot-Marie-Tooth disease AR 16 8 PMP22 Neuropathy, inflammatory demyelinating, Roussy-Levy syndrome, AD/AR 49 165 Dejerine-Sottas disease, Neuropathy, hereditary, with liability to pressurve palsies, Charcot-Marie-Tooth disease POLG POLG-related ataxia neuropathy spectrum disorders, Sensory ataxia, AD/AR 89 290 dysarthria, and ophthalmoparesis, Alpers syndrome, Progressive external ophthalmoplegia with mitochondrial DNA deletions, Mitochondrial DNA depletion syndrome PRDM12 Neuropathy, hereditary sensory and autonomic, type VIII AR 7 11 PRPS1* Phosphoribosylpyrophosphate synthetase I superactivity, Arts syndrome, XL 27 32 Charcot-Marie-Tooth disease, X-linked recessive, 5, Deafness, X-linked 1 PRX Dejerine-Sottas disease, Charcot-Marie-Tooth disease AR 26 55 RAB7A Charcot-Marie-Tooth disease AD 5 7 REEP1 Spastic paraplegia, Distal hereditary motor neuronopathy AD 16 60 SACS Spastic ataxia, Charlevoix-Saguenay AR 254 262 SBF1 Charcot-Marie-Tooth disease AR 5 10 SBF2 Charcot-Marie-Tooth disease AR 25 21 SCN11A Episodic pain syndrome, familial, 3, Neuropathy, hereditary sensory and AD 8 20 autonomic, type VII SCN9A Paroxysmal extreme pain disorder, Small fiber neuropathy, Erythermalgia, AD/AR 61 125 primary, Generalized epilepsy with febrile seizures plus, type 7, Insensitivity to pain, congenital, autosomal recessive SCYL1 Spinocerebellar ataxia, autosomal recessive 21 AR 12 6 SEPT9 Amyotrophy, hereditary neuralgic AD 4 11 SETX Ataxia with oculomotor apraxia, Amyotrophic lateral sclerosis, juvenile, AD/AR 36 210 Spinocerebellar ataxia SH3TC2 Mononeuropathy of the median nerve, Charcot-Marie-Tooth disease AR 63 89 SLC12A6 Agenesis of the corpus callosum with peripheral neuropathy (Andermann AD/AR 43 19 syndrome) SLC25A46 Neuropathy, hereditary motor and sensory, type VIB AR 14 17 https://blueprintgenetics.com/ SMAD3 Aneurysms-osteoarthritis syndrome, Loeys-Dietz syndrome AD 48 82 SPG11 Spastic paraplegia, Amyotrophic lateral sclerosis, Charcot-Marie-Tooth AR 162 274 disease SPTBN4 Myopathy, congenital, with neuropathy and deafness AR 6 7 SPTLC1* Neuropathy, hereditary sensory and autonomic AD 8 11 SPTLC2 Hereditary sensory and autonomic neuropathy AD 5 14 SURF1 Leigh syndrome, Charcot-Marie-Tooth disease AR 50 101 TFG Spastic paraplegia, Hereditary motor and sensory neuropathy, proximal AR 4 7 TRIM2 Charcot-Marie-Tooth disease AR 5 8 TRPV4 Metatropic dysplasia, Spondyloepiphyseal dysplasia Maroteaux type, AD 61 78 Parastremmatic dwarfism, Hereditary motor and sensory neuropathy, Spondylometaphyseal dysplasia Kozlowski type, Spinal muscular atrophy, Charcot-Marie-Tooth disease, Brachyolmia (autosomal dominant type), Familial Digital arthropathy with brachydactyly TTR Dystransthyretinemic hyperthyroxinemia, Amyloidosis, hereditary, AD 52 148 transthyretin-related TYMP Mitochondrial
Recommended publications
  • COX10 (NM 001303) Human Untagged Clone Product Data

    COX10 (NM 001303) Human Untagged Clone Product Data

    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for SC119292 COX10 (NM_001303) Human Untagged Clone Product data: Product Type: Expression Plasmids Product Name: COX10 (NM_001303) Human Untagged Clone Tag: Tag Free Symbol: COX10 Synonyms: MC4DN3 Vector: pCMV6-XL5 E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: None Fully Sequenced ORF: >NCBI ORF sequence for NM_001303, the custom clone sequence may differ by one or more nucleotides ATGGCCGCATCTCCGCACACTCTCTCCTCACGCCTCCTGACAGGTTGCGTAGGAGGCTCTGTCTGGTATC TTGAAAGAAGAACTATACAGGACTCCCCTCACAAGTTCTTACATCTTCTCAGGAATGTCAATAAGCAGTG GATTACATTTCAGCACTTTAGCTTCCTCAAACGCATGTATGTCACACAGCTGAACAGAAGCCACAACCAG CAAGTAAGACCCAAGCCAGAACCAGTAGCATCTCCTTTCCTTGAAAAAACATCTTCAGGTCAAGCCAAAG CAGAAATATATGAGATGAGACCTCTCTCACCGCCCAGCCTATCTTTGTCCAGAAAGCCAAATGAAAAGGA ATTGATAGAACTAGAGCCAGACTCAGTAATTGAAGACTCAATAGATGTAGGGAAAGAGACAAAAGAGGAA AAGCGGTGGAAAGAGATGAAGCTGCAAGTGTATGATTTGCCAGGAATTTTGGCTCGACTATCCAAAATCA AACTCACAGCTCTGGTTGTAAGTACCACTGCAGCTGGATTTGCATTGGCTCCGGGCCCTTTTGACTGGCC CTGTTTCCTGCTTACTTCTGTTGGGACAGGCCTTGCATCCTGTGCTGCCAACTCCATCAATCAGTTTTTT GAGGTGCCATTTGACTCAAACATGAATAGGACAAAGAACAGACCGCTGGTTCGTGGACAGATCAGCCCAT TGCTAGCTGTGTCCTTTGCCACTTGTTGTGCTGTTCCGGGAGTTGCCATTCTGACCTTGGGGGTGAATCC ACTCACAGGAGCCCTGGGGCTCTTCAACATTTTCCTGTATACCTGCTGCTACACACCACTGAAAAGGATC AGCATTGCCAACACATGGGTCGGAGCTGTGGTTGGGGCCATCCCGCCTGTCATGGGCTGGACAGCGGCCA CGGGCAGCCTCGATGCTGGCGCATTTCTCCTGGGAGGAATCCTCTACTCCTGGCAGTTTCCTCATTTCAA
  • The National Economic Burden of Rare Disease Study February 2021

    The National Economic Burden of Rare Disease Study February 2021

    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
  • Inherited Neuropathies

    Inherited Neuropathies

    407 Inherited Neuropathies Vera Fridman, MD1 M. M. Reilly, MD, FRCP, FRCPI2 1 Department of Neurology, Neuromuscular Diagnostic Center, Address for correspondence Vera Fridman, MD, Neuromuscular Massachusetts General Hospital, Boston, Massachusetts Diagnostic Center, Massachusetts General Hospital, Boston, 2 MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology Massachusetts, 165 Cambridge St. Boston, MA 02114 and The National Hospital for Neurology and Neurosurgery, Queen (e-mail: [email protected]). Square, London, United Kingdom Semin Neurol 2015;35:407–423. Abstract Hereditary neuropathies (HNs) are among the most common inherited neurologic Keywords disorders and are diverse both clinically and genetically. Recent genetic advances have ► hereditary contributed to a rapid expansion of identifiable causes of HN and have broadened the neuropathy phenotypic spectrum associated with many of the causative mutations. The underlying ► Charcot-Marie-Tooth molecular pathways of disease have also been better delineated, leading to the promise disease for potential treatments. This chapter reviews the clinical and biological aspects of the ► hereditary sensory common causes of HN and addresses the challenges of approaching the diagnostic and motor workup of these conditions in a rapidly evolving genetic landscape. neuropathy ► hereditary sensory and autonomic neuropathy Hereditary neuropathies (HN) are among the most common Select forms of HN also involve cranial nerves and respiratory inherited neurologic diseases, with a prevalence of 1 in 2,500 function. Nevertheless, in the majority of patients with HN individuals.1,2 They encompass a clinically heterogeneous set there is no shortening of life expectancy. of disorders and vary greatly in severity, spanning a spectrum Historically, hereditary neuropathies have been classified from mildly symptomatic forms to those resulting in severe based on the primary site of nerve pathology (myelin vs.
  • Experiences of Rare Diseases: an Insight from Patients and Families

    Experiences of Rare Diseases: an Insight from Patients and Families

    Experiences of Rare Diseases: An Insight from Patients and Families Unit 4D, Leroy House 436 Essex Road London N1 3QP tel: 02077043141 fax: 02073591447 [email protected] www.raredisease.org.uk By Lauren Limb, Stephen Nutt and Alev Sen - December 2010 Web and press design www.raredisease.org.uk WordsAndPeople.com About Rare Disease UK Rare Disease UK (RDUK) is the national alliance for people with rare diseases and all who support them. Our membership is open to all and includes patient organisations, clinicians, researchers, academics, industry and individuals with an interest in rare diseases. RDUK was established by Genetic RDUK is campaigning for a Alliance UK, the national charity strategy for integrated service of over 130 patient organisations delivery for rare diseases. This supporting all those affected by would coordinate: genetic conditions, in conjunction with other key stakeholders | Research in November 2008 following the European Commission’s | Prevention and diagnosis Communication on Rare Diseases: | Treatment and care Europe’s Challenges. | Information Subsequently RDUK successfully | Commissioning and planning campaigned for the adoption of the Council of the European into one cohesive strategy for all Union’s Recommendation on patients affected by rare disease in an action in the field of rare the UK. As well as securing better diseases. The Recommendation outcomes for patients, a strategy was adopted unanimously by each would enable the most effective Member State of the EU (including use of NHS resources. the

  • The Modulation of Sphingolipids by Human Cytomegalovirus and Its Influence on Viral Protein Accumulation and Growth

    THE MODULATION OF SPHINGOLIPIDS BY HUMAN CYTOMEGALOVIRUS AND ITS INFLUENCE ON VIRAL PROTEIN ACCUMULATION AND GROWTH DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Nicholas John Machesky, B.S. ***** The Ohio State University 2007 Dissertation Committee: Approved by Professor James R. Van Brocklyn, Advisor Professor Joanne Trgovcich _________________________________ Professor W. James Waldman Advisor Integrated Biomedical Science Graduate Program Professor Chien-Liang Lin ABSTRACT Human cytomegalovirus (HCMV) is a β-herpes virus which can cause serious disease and even death in congenitally-infected infants and in immunocompromised individuals or immunosuppressed transplant recipients. This virus promotes its own replication by exploiting many cellular signaling pathways. Sphingolipids are structural components of cell membranes which can act as critical mediators of cell signaling. Sphingosine kinase (SphK) can phosphorylate dihydrosphingosine (dhSph) and sphingosine (Sph) to produce dihydrosphingosine-1-phosphate (dhS1P) and sphingosine- 1-phosphate (S1P), respectively, which can activate many signaling pathways through binding to G-protein coupled S1P receptors, named S1P1-5. An area of research which has yet to be elucidated is whether HCMV modulates sphingolipids and their signaling pathways. Our data show that HCMV infection results in increased accumulation and activity of sphingosine kinase (SphK) within different cell types. This occurs during early times of infection in that it occurs after virus entry but before replication of viral DNA. Measuring the levels of transcripts encoding key enzymes of the sphingolipid metabolic pathway during HCMV infection revealed a temporal regulation of both synthetic and degradative enzymes of this pathway.
  • Absence of NEFL in Patient-Specific Neurons in Early-Onset Charcot-Marie-Tooth Neuropathy Markus T

    Absence of NEFL in Patient-Specific Neurons in Early-Onset Charcot-Marie-Tooth Neuropathy Markus T

    ARTICLE OPEN ACCESS Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy Markus T. Sainio, MSc, Emil Ylikallio, MD, PhD, Laura M¨aenp¨a¨a, MSc, Jenni Lahtela, PhD, Pirkko Mattila, PhD, Correspondence Mari Auranen, MD, PhD, Johanna Palmio, MD, PhD, and Henna Tyynismaa, PhD Dr. Tyynismaa [email protected] Neurol Genet 2018;4:e244. doi:10.1212/NXG.0000000000000244 Abstract Objective We used patient-specific neuronal cultures to characterize the molecular genetic mechanism of recessive nonsense mutations in neurofilament light (NEFL) underlying early-onset Charcot- Marie-Tooth (CMT) disease. Methods Motor neurons were differentiated from induced pluripotent stem cells of a patient with early- onset CMT carrying a novel homozygous nonsense mutation in NEFL. Quantitative PCR, protein analytics, immunocytochemistry, electron microscopy, and single-cell transcriptomics were used to investigate patient and control neurons. Results We show that the recessive nonsense mutation causes a nearly total loss of NEFL messenger RNA (mRNA), leading to the complete absence of NEFL protein in patient’s cultured neurons. Yet the cultured neurons were able to differentiate and form neuronal networks and neuro- filaments. Single-neuron gene expression fingerprinting pinpointed NEFL as the most down- regulated gene in the patient neurons and provided data of intermediate filament transcript abundancy and dynamics in cultured neurons. Blocking of nonsense-mediated decay partially rescued the loss of NEFL mRNA. Conclusions The strict neuronal specificity of neurofilament has hindered the mechanistic studies of re- cessive NEFL nonsense mutations. Here, we show that such mutation leads to the absence of NEFL, causing childhood-onset neuropathy through a loss-of-function mechanism.
  • Peripheral Neuropathy in Complex Inherited Diseases: an Approach To

    Peripheral Neuropathy in Complex Inherited Diseases: an Approach To

    PERIPHERAL NEUROPATHY IN COMPLEX INHERITED DISEASES: AN APPROACH TO DIAGNOSIS Rossor AM1*, Carr AS1*, Devine H1, Chandrashekar H2, Pelayo-Negro AL1, Pareyson D3, Shy ME4, Scherer SS5, Reilly MM1. 1. MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 2. Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 3. Unit of Neurological Rare Diseases of Adulthood, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy. 4. Department of Neurology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA 5. Department of Neurology, University of Pennsylvania, Philadelphia, PA 19014, USA. * These authors contributed equally to this work Corresponding author: Mary M Reilly Address: MRC Centre for Neuromuscular Diseases, 8-11 Queen Square, London, WC1N 3BG, UK. Email: [email protected] Telephone: 0044 (0) 203 456 7890 Word count: 4825 ABSTRACT Peripheral neuropathy is a common finding in patients with complex inherited neurological diseases and may be subclinical or a major component of the phenotype. This review aims to provide a clinical approach to the diagnosis of this complex group of patients by addressing key questions including the predominant neurological syndrome associated with the neuropathy e.g. spasticity, the type of neuropathy, and the other neurological and non- neurological features of the syndrome. Priority is given to the diagnosis of treatable conditions. Using this approach, we associated neuropathy with one of three major syndromic categories - 1) ataxia, 2) spasticity, and 3) global neurodevelopmental impairment. Syndromes that do not fall easily into one of these three categories can be grouped according to the predominant system involved in addition to the neuropathy e.g.
  • Restoration of Epithelial Sodium Channel Function by Synthetic Peptides in Pseudohypoaldosteronism Type 1B Mutants

    Restoration of Epithelial Sodium Channel Function by Synthetic Peptides in Pseudohypoaldosteronism Type 1B Mutants

    ORIGINAL RESEARCH published: 24 February 2017 doi: 10.3389/fphar.2017.00085 Restoration of Epithelial Sodium Channel Function by Synthetic Peptides in Pseudohypoaldosteronism Type 1B Mutants Anita Willam 1*, Mohammed Aufy 1, Susan Tzotzos 2, Heinrich Evanzin 1, Sabine Chytracek 1, Sabrina Geppert 1, Bernhard Fischer 2, Hendrik Fischer 2, Helmut Pietschmann 2, Istvan Czikora 3, Rudolf Lucas 3, Rosa Lemmens-Gruber 1 and Waheed Shabbir 1, 2 1 Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria, 2 APEPTICO GmbH, Vienna, Austria, 3 Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA Edited by: The synthetically produced cyclic peptides solnatide (a.k.a. TIP or AP301) and its Gildas Loussouarn, congener AP318, whose molecular structures mimic the lectin-like domain of human University of Nantes, France tumor necrosis factor (TNF), have been shown to activate the epithelial sodium Reviewed by: channel (ENaC) in various cell- and animal-based studies. Loss-of-ENaC-function Stephan Kellenberger, University of Lausanne, Switzerland leads to a rare, life-threatening, salt-wasting syndrome, pseudohypoaldosteronism type Yoshinori Marunaka, 1B (PHA1B), which presents with failure to thrive, dehydration, low blood pressure, Kyoto Prefectural University of Medicine, Japan anorexia and vomiting; hyperkalemia, hyponatremia and metabolic acidosis suggest *Correspondence: hypoaldosteronism, but plasma aldosterone and renin activity are high. The aim of Anita Willam the present study was to investigate whether the ENaC-activating effect of solnatide [email protected] and AP318 could rescue loss-of-function phenotype of ENaC carrying mutations at + Specialty section: conserved amino acid positions observed to cause PHA1B.
  • Redefining the Specificity of Phosphoinositide-Binding by Human

    Redefining the Specificity of Phosphoinositide-Binding by Human

    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.20.163253; this version posted June 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Redefining the specificity of phosphoinositide-binding by human PH domain-containing proteins Nilmani Singh1†, Adriana Reyes-Ordoñez1†, Michael A. Compagnone1, Jesus F. Moreno Castillo1, Benjamin J. Leslie2, Taekjip Ha2,3,4,5, Jie Chen1* 1Department of Cell & Developmental Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801; 2Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205; 3Department of Biophysics, Johns Hopkins University, Baltimore, MD 21218; 4Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205; 5Howard Hughes Medical Institute, Baltimore, MD 21205, USA †These authors contributed equally to this work. *Correspondence: [email protected]. bioRxiv preprint doi: https://doi.org/10.1101/2020.06.20.163253; this version posted June 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. ABSTRACT Pleckstrin homology (PH) domains are presumed to bind phosphoinositides (PIPs), but specific interaction with and regulation by PIPs for most PH domain-containing proteins are unclear. Here we employed a single-molecule pulldown assay to study interactions of lipid vesicles with full-length proteins in mammalian whole cell lysates.
  • Inherited Renal Tubulopathies—Challenges and Controversies

    Inherited Renal Tubulopathies—Challenges and Controversies

    G C A T T A C G G C A T genes Review Inherited Renal Tubulopathies—Challenges and Controversies Daniela Iancu 1,* and Emma Ashton 2 1 UCL-Centre for Nephrology, Royal Free Campus, University College London, Rowland Hill Street, London NW3 2PF, UK 2 Rare & Inherited Disease Laboratory, London North Genomic Laboratory Hub, Great Ormond Street Hospital for Children National Health Service Foundation Trust, Levels 4-6 Barclay House 37, Queen Square, London WC1N 3BH, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-2381204172; Fax: +44-020-74726476 Received: 11 February 2020; Accepted: 29 February 2020; Published: 5 March 2020 Abstract: Electrolyte homeostasis is maintained by the kidney through a complex transport function mostly performed by specialized proteins distributed along the renal tubules. Pathogenic variants in the genes encoding these proteins impair this function and have consequences on the whole organism. Establishing a genetic diagnosis in patients with renal tubular dysfunction is a challenging task given the genetic and phenotypic heterogeneity, functional characteristics of the genes involved and the number of yet unknown causes. Part of these difficulties can be overcome by gathering large patient cohorts and applying high-throughput sequencing techniques combined with experimental work to prove functional impact. This approach has led to the identification of a number of genes but also generated controversies about proper interpretation of variants. In this article, we will highlight these challenges and controversies. Keywords: inherited tubulopathies; next generation sequencing; genetic heterogeneity; variant classification. 1. Introduction Mutations in genes that encode transporter proteins in the renal tubule alter kidney capacity to maintain homeostasis and cause diseases recognized under the generic name of inherited tubulopathies.
  • De Novo, Systemic, Deleterious Amino Acid Substitutions Are Common in Large Cytoskeleton‑Related Protein Coding Regions

    De Novo, Systemic, Deleterious Amino Acid Substitutions Are Common in Large Cytoskeleton‑Related Protein Coding Regions

    BIOMEDICAL REPORTS 6: 211-216, 2017 De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton‑related protein coding regions REBECCA J. STOLL1, GRACE R. THOMPSON1, MOHAMMAD D. SAMY1 and GEORGE BLANCK1,2 1Department of Molecular Medicine, Morsani College of Medicine, University of South Florida; 2Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA Received June 13, 2016; Accepted October 31, 2016 DOI: 10.3892/br.2016.826 Abstract. Human mutagenesis is largely random, thus large Introduction coding regions, simply on the basis of probability, represent relatively large mutagenesis targets. Thus, we considered Genetic damage is largely random and therefore tends to the possibility that large cytoskeletal-protein related coding affect the larger, functional regions of the human genome regions (CPCRs), including extra-cellular matrix (ECM) more frequently than the smaller regions (1). For example, coding regions, would have systemic nucleotide variants that a systematic study has revealed that cancer fusion genes, on are not present in common SNP databases. Presumably, such average, are statistically, significantly larger than other human variants arose recently in development or in recent, preceding genes (2,3). The large introns of potential cancer fusion genes generations. Using matched breast cancer and blood-derived presumably allow for many different productive recombina- normal datasets from the cancer genome atlas, CPCR single tion opportunities, i.e., many recombinations that would allow nucleotide variants (SNVs) not present in the All SNPs(142) for exon juxtaposition and the generation of hybrid proteins. or 1000 Genomes databases were identified. Using the Protein Smaller cancer fusion genes tend to be associated with the rare Variation Effect Analyzer internet-based tool, it was discov- types of cancer, for example EWS RNA binding protein 1 in ered that apparent, systemic mutations (not shared among Ewing's sarcoma.
  • NICU Gene List Generator.Xlsx

    NICU Gene List Generator.Xlsx

    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2